ÑëÊÓÍø|ÖйúÍøÂçµçÊǪ́|ÍøÕ¾µØͼ |
¿Í·þÉèΪÊ×Ò³ |
ÖйúÍøÂçµçÊǪ́ > ÐÂÎĄ̊ > ÐÂÎÅÖÐÐÄ >
·¢²¼Ê±¼ä:2012Äê07ÔÂ26ÈÕ 21:34 | ½øÈ븴ÐËÂÛ̳ | À´Ô´£ºÖйú½ÌÓýÍø | ÊÖ»ú¿´ÊÓƵ
΢·Ã̸ | ΢ֱ²¥ | ΢¹ã³¡ | ÃûÈËǽ | ÅÅÐаñ
• ³È×Ó´òÀ¯¸ÃÈçºÎʶ±ð • ½ÒÃؼßÊ®ÑÐÖÆÈ«¹ý³Ì
¡¡¡¡Öйú½ÌÓýÍøѶ£º½üÒ»ÄêÀ´£¬¹ú¼ÊѪҺѧÁìÓòµÄ¶¥¼¶Ñ§ÊõÆÚ¿¯¡¶Blood¡·£¨Ó°ÏìÒò×Ó10.588£©Á¬Ðø·¢±íÁ˱±¾©´óѧѪҺ²¡Ñо¿Ëù»ÆÏþ¾ü¿ÎÌâ×éÍê³ÉµÄÈýƪѧÊõÂÛÎÄ£¬±¨µÀÁ˸ÿÎÌâ×éÔÚÔìѪ¸Éϸ°ûÒÆÖ²ÖÎÁƶñÐÔѪҺ²¡·½ÃæÈ¡µÃµÄһϵÁд´ÐÂÐÔÑо¿³É¹û¡£»ÆÏþ¾ü½ÌÊÚ»¹Ó¦Ñû¾Í¡°µ¥±¶ÌåÏàºÏÔìѪ¸Éϸ°ûÒÆÖ²ÎÊÌ⡱ÔÚ¡¶Seminar in Oncology¡·ÒÔ¼°¡¶Current Opinion in Hematology¡·ÉÏ׫дÁËרÌâ×ÛÊö¡£
¡¡¡¡Ä¿Ç°£¬ÔìѪ¸ÉϸÒÆÖ²ÈÔÊǶñÐÔѪҺ²¡ÓÐЧÄËÖÁΨһµÄ¸ùÖÎÊֶΡ£ÔÚÎÒ¹ú£¬ÓÉÓÚ¶ÀÉú×ÓÅ®Õþ²ßµÄʵʩ¼°Æê´øѪºÍÎ޹ع©Õß¹ÇËè¿â¹æÄ£µÄÏÞÖÆ£¬Ðí¶à»¼ÕߺÜÄÑÕÒµ½ºÏÊʵĹ©Õß¡£»ÆÏþ¾ü½ÌÊÚ¿ÎÌâ×é¶àÄêÀ´µÄÑо¿Ö¤Êµ£¬µ¥±¶ÌåÏàºÏÔìѪ¸Éϸ°ûÒÆÖ²¿ÉÓÐЧÖÎÁÆ°×Ѫ²¡¡¢ÁÜ°ÍÁö¼°¹ÇËèÔöÉúÒì³£×ÛºÏÕ÷µÈ¶ñÐÔѪҺ²¡£¬´ïµ½ÁËÓëÈËÀà°×ϸ°û·Ö»¯¿¹Ô£¨HLA£©ÏàºÏͬ°ûºÍÎ޹ع©ÕßÒÆÖ²µÈͬµÄÁÆЧ£¬¿ÎÌâ×黹½«µ¥±¶ÌåÏàºÏÔìѪ¸Éϸ°ûÒÆÖ²µÄÊÊÓ¦Ö¢À©Õ¹µ½ÔÙÉúÕÏ°ÐÔƶѪµÈ¼²²¡£¬´Ó¶ø³¹µ×½â¾öÁ˹©ÕßÀ´Ô´È±·¦µÄÎÊÌâ¡£ÔÚ´Ë»ù´¡ÉÏ£¬¿ÎÌâ×é·¢ÏÖHLAÏàºÏͬ°û/µ¥±¶ÌåÏàºÏÔìѪ¸Éϸ°ûÒÆÖ²ÖÎÁƼÓËÙÆڵĵÍΣÂýÐÔÁ£Ï¸°û°×Ѫ²¡»¼Õߣ¬ÆäÁÆЧÓëÒÁÂíÌæÄáÏ൱£»µ«ÊǶÔÓÚ¸ßΣ»¼Õߣ¬ HLAÏàºÏͬ°û/µ¥±¶ÌåÏàºÏÔìѪ¸Éϸ°ûÒÆÖ²ÖÎÁƽϽÓÊÜÒÁÂíÌæÄáÖÎÁƾßÓÐÏÔÖøµÄÉú´æÓÅÊÆ£¨Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase,Blood,2011,117:303£©£¬¸ÃÑо¿³É¹ûÒѱ»¡¶ÖйúÂýÐÔËèϵ°×Ѫ²¡Õï¶ÏºÍÖÎÁÆÖ¸ÄÏ£¨2011°æ£©¡·ËùÒýÓ㬶ԼÓËÙÆÚÂýÐÔËèϸ°û°×Ѫ²¡µÄÖÎÁƾßÓкܺõÄÖ¸µ¼ÒâÒå¡£
¡¡¡¡¼±ÐÔËèϸ°û°×Ѫ²¡»¼ÕßµÚÒ»´Î»º½â£¨CR1£©ºóµÄÖÎÁƶÔÓÚ»¼Õߵij¤ÆÚÉú´æÖÁ¹ØÖØÒª¡£¶ÔÓÚ»ñµÃCR1µÄÖС¢¸ßΣ¼±ÐÔËèϸ°û°×Ѫ²¡»¼Õ߶øÑÔ£¬Å·ÖÞ°×Ѫ²¡Ð×÷×éÖ¯ÍƼöÓÅÏÈÑ¡Ôñ£¨the European LeukemiaNet£©HLAÏàºÏͬ°ûÒÆÖ²£»Ä¿Ç°£¬µ¥±¶ÌåÏàºÏÔìѪ¸Éϸ°ûÒÆÖ²ÔÚÖС¢¸ßΣ¼±ÐÔËèϸ°û°×Ѫ²¡»º½âºóÖÎÁÆÖеĵØλ»¹²»Çå³þ¡£»ÆÏþ¾ü¿ÎÌâ×é·¢ÏÖµ¥±¶ÌåÏàºÏÔìѪ¸Éϸ°ûÒÆÖ²ÖÎÁÆCR1µÄÖС¢¸ßΣ¼±ÐÔËèϸ°û°×Ѫ²¡ÁÆЧÏÔÖøÓÅÓÚµ¥¶À»¯ÁÆ×飨The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission,Blood,2012,119:5584£©£¬¸ÃÑо¿³É¹ûÌáʾµ¥±¶ÌåÏàºÏÔìѪ¸Éϸ°ûÒÆÖ²¿É×÷ΪÎÞHLAÏàºÏ¹©ÕßµÄÖС¢¸ßΣ¼±ÐÔËèϸ°û°×Ѫ²¡»¼ÕßCR1ºó¹®¹ÌÖÎÁƵÄÒ»¸öÖØÒªÖÎÁƲßÂÔ¡£
¡¡¡¡°×Ѫ²¡¸´·¢ÊÇÔìѪ¸Éϸ°ûÒÆÖ²µÄÖ÷ÒªËÀÍöÔÒòÖ®Ò»¡£Õë¶ÔÒÆÖ²ºó¸´·¢ÎÊÌ⣬»ÆÏþ¾ü¿ÎÌâ×é½èÖúWT1»ùÒòÒÔ¼°¶à²ÎÊýÁ÷ʽϸ°ûÒǵȴӱêΣ»¼ÕßÖÐɸѡ³ö¸´·¢¸ßΣ»¼Õߣ¬²¢¶ÔÕâЩ»¼Õß½øÐÐÔ¤·ÀÐÔ¹©ÕßÁÜ°Íϸ°û»ØÊ䣬½á¹ûÏÔÖø½µµÍÁ˸´·¢ÂÊ£¬Ìá¸ßÁËÁÆЧ£¬´Ó¸´·¢Ô¤·À½Ç¶ÈÍêÉÆÁËHLAÏàºÏͬ°û/µ¥±¶ÌåÏàºÏÔìѪ¸Éϸ°ûÒÆÖ²Ìåϵ£¬Ìá¸ßÁË»¼Õß³¤ÆÚÉú´æÂÊ¡¢¸ÄÉÆÁËÒÆÖ²Ô¤ºó(Risk stratification¨Cdirected donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation,Blood,2012,119:3256£©¡£»ÆÏþ¾ü¿ÎÌâ×éµÄϵÁÐÑо¿µÃµ½Á˹ú¼Ò×ÔÈ»¿Æѧ»ù½ð½Ü³öÇàÄê»ù½ð£¬¡°863¡±»ù½ðÒÔ¼°ÎÀÉú²¿Ò½ÔºÁÙ´²Ñ§¿ÆÖصãÏîÄ¿µÈ¶àÏî¿ÆÑлù½ðµÄ×ÊÖú¡£
¡¡¡¡¸ü¶à¸Éϸ°ûÇëµã»÷´Ë´¦